Our survey addressed testing rates by NSCLC histology, mutations with more recently approved targeted therapy (TRK, RET, MET), plus those with therapy under approval consideration (KRAS, HER2) at the time of survey conduction. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.